Acumen Pharmaceuticals (ABOS) Other Non Operating Income (2021 - 2026)
Acumen Pharmaceuticals (ABOS) reported Other Non Operating Income of $460000.0 for Q1 2026, up 142.11% on a YoY basis from $190000.0 in Q1 2025, and up 332.32% sequentially from -$198000.0 in Q4 2025.
Acumen Pharmaceuticals (ABOS) Other Non Operating Income (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 6 years of Other Non Operating Income data on file, last reported at $460000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 142.11% year-over-year to $460000.0; the trailing twelve-month figure through Mar 2026 stood at $153000.0 (up 114.18% YoY), and the FY2025 full-year result was -$460000.0, down 204.64% from the prior year.
- Other Non Operating Income rose to $460000.0 in Q1 2026, from -$198000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $460000.0 in Q1 2026 to a low of -$1.2 million in Q4 2024.
- A 5-year average of -$72571.4 and a median of -$15500.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income plunged 5571.43% in 2024 and soared 451.85% in 2025, its largest moves.
- Tracing ABOS's Other Non Operating Income over 5 years: stood at -$10000.0 in 2022, then plunged by 110.0% to -$21000.0 in 2023, then sank by 5571.43% to -$1.2 million in 2024, then soared by 83.38% to -$198000.0 in 2025, then surged by 332.32% to $460000.0 in 2026.
- Business Quant data shows ABOS's Other Non Operating Income at $460000.0 in Q1 2026, -$198000.0 in Q4 2025, and -$69000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Acumen Pharmaceuticals | 138.13 Mn | 138.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 460,000.00 |
| Dec 31, 2025 | -198,000.00 |
| Sep 30, 2025 | -69,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Dec 31, 2024 | -1.19 Mn |
| Sep 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -68,000.00 |
| Mar 31, 2024 | -54,000.00 |
| Dec 31, 2023 | -21,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | -10,000.00 |
| Sep 30, 2022 | -2,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | 19,000.00 |
| Mar 31, 2021 | 9,000.00 |